Autolus Therapeutics plc ADR (NASDAQ:AUTL) shares, rose in value on Wednesday, July 09, with the stock price up by 4.66% to the previous day’s close as strong demand from buyers drove the stock to $2.47.
Actively observing the price movement in the last trading, the stock closed the session at $2.36, falling within a range of $2.3671 and $2.53. The value of beta (5-year monthly) was 1.739. Referring to stock’s 52-week performance, its high was $5.00, and the low was $1.11. On the whole, AUTL has fluctuated by 5.56% over the past month.
With the market capitalization of Autolus Therapeutics plc ADR currently standing at about $657.37 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AUTL’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of AUTL currently trading nearly 10.19% and 34.53% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 69.77, while the 7-day volatility ratio is showing 6.08% which for the 30-day chart, stands at 5.99%. Furthermore, Autolus Therapeutics plc ADR (AUTL)’s beta value is 1.89.
A comparison of Autolus Therapeutics plc ADR (AUTL) with its peers suggests the former has fared considerably weaker in the market. AUTL showed an intraday change of 4.66% in last session, and over the past year, it grew by 5.11%%.
Data on historical trading for Autolus Therapeutics plc ADR (NASDAQ:AUTL) indicates that the trading volumes over the past 10 days have averaged 1.66 and over the past 3 months, they’ve averaged 2.33 million. According to company’s latest data on outstanding shares, there are 266.14 million shares outstanding.
Nearly 9.70% of Autolus Therapeutics plc ADR’s shares belong to company insiders and institutional investors own 60.22% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.71 million shares as on 2025-06-13, resulting in a short ratio of 5.19. According to the data, the short interest in Autolus Therapeutics plc ADR (AUTL) stood at 629.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 10.59 million. The stock has fallen by -28.41% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AUTL stock heading into the next quarter.
